Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Novolin R, in Healthy Subjects.

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Wockhardt
ClinicalTrials.gov Identifier:
NCT00596063
First received: January 7, 2008
Last updated: December 26, 2012
Last verified: December 2012

January 7, 2008
December 26, 2012
January 2008
February 2008   (final data collection date for primary outcome measure)
The primary objective is to test for bioequivalence based on AUC0-12h and Cmax between Wockhardt's Insulin Human Regular for injection and Novolin® R [ Time Frame: Visit 2 & 3 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00596063 on ClinicalTrials.gov Archive Site
PK endpoints: AUC, tmax and t½ PD endpoints: AUC-GIR, GIRmax and tGIRmax Safety endpoints: AEs, haematology, biochemistry, urinalyses, physical examination, vital signs, ECGs, blood glucose and local tolerability. [ Time Frame: Visit 2, 3 and 4 ] [ Designated as safety issue: Yes ]
Same as current
Not Provided
Not Provided
 
Comparative Glucose Clamp Study of Wockhardt's Insulin Human Regular for Injection and Novolin R, in Healthy Subjects.
A Randomized, Single Center, Double Blind, Two Period, Crossover Glucose Clamp Study to Test for Bioequivalence Between Two Recombinant Human Soluble Insulins- Wockhardts Insulin Human Regular for Injection and Novolin R in Healthy Subjects

The purpose of this study is the comparative evaluation of the pharmacokinetics and pharmacodynamics of two recombinant regular human insulin injections administered subcutaneously in healthy volunteers under the conditions of euglycemic clamp.

A comparative evaluation of the pharmacokinetics and pharmacodynamics of two recombinant regular human insulin injections administered subcutaneously in healthy volunteers. It is a crossover study. The subjects shall be administered single doses of each insulin during two separate visits under the conditions of euglycemic clamp.

Interventional
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Diabetes Mellitus
  • Biological: Wosulin R
    Penfill cartridges; Single Dose, 0.2 IU/ kg;
  • Biological: Novolin R
    Penfill cartridges; Single Dose, 0.2 IU/ kg;
  • Experimental: Wosulin R
    Regular insulin for subcutaneous injection (recombinant human insulin), 600nmol, 100 IU
    Intervention: Biological: Wosulin R
  • Active Comparator: Novolin R
    Regular insulin for injection (recombinant human insulin)
    Intervention: Biological: Novolin R
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
25
February 2008
February 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Healthy male or female subject.
  2. Age ≥ 18 and ≤ 45 years.
  3. Body Mass Index (BMI) between 18.0 and 27.0 kg/m2, inclusive.
  4. Non-smoker, defined as no nicotine consumption for at least one year.
  5. Signed and dated informed consent obtained before any trial-related activities. (Trial-related activities are any procedure that would not have been performed during normal management of the subject.).

Exclusion Criteria:

  1. Previous participation in this trial or other clinical trials within the last 3 months.
  2. Pregnant, breast-feeding or the intention of becoming pregnant or not using adequate contraceptive measures (intrauterine device (IUD) that has been in place for at least 3 months, or sterilization, or the oral contraceptive pill, which should have been taken without difficulty for at least 3 months, an approved hormonal implant).
  3. Clinically significant abnormal hematology or biochemistry screening tests, as judged by the Investigator. In particular, subjects with elevated liver enzymes (AST or ALT > 2 times the upper limit of normal) or impaired renal function (elevated serum creatinine values above the upper limit of normal) will not be allowed to enter the trial.
  4. Any serious systemic infectious disease during the four weeks prior to the first dose of test drug, as judged by the Investigator.
  5. History of any illness that, in the opinion of the Investigator, might confound the results of the trial or pose risk in administering the trial drug to the subject. In particular, subjects with significant cardiovascular disease, anemia (haemoglobin below the lower limit of normal) or hemoglobinopathy will not be allowed to enter the trial.
  6. History of alcohol or drug abuse.
  7. Any positive reaction of drugs of abuse.
  8. Hepatitis B or C or HIV positive.
  9. Use of prescription drugs within 3 weeks preceding the first dosing of insulin, except for oral contraceptives/hormonal implants.
  10. Use of any insulin product for therapeutic purposes in the past.
  11. Use of non-prescription drugs, except routine vitamins, within 3 weeks prior to the first dose of the test drug. Occasional use of paracetamol is permitted.
  12. Mental incapacity, unwillingness or language barriers precluding adequate understanding or co-operation.
  13. Blood donation of more than 500 ml within the last 12 weeks.
  14. History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction.
  15. Known or suspected allergy to trial product or related products.
Both
18 Years to 45 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00596063
Wosulin R/PK-PD/HV/FDA/07/v1, Not yet created
No
Wockhardt
Wockhardt
Not Provided
Principal Investigator: Linda Morrow, M.D Profil Institute for Clinical Research, Inc.
Wockhardt
December 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP